Cargando…
SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain
Autores principales: | Lens, Sabela, Miquel, Mireia, Mateos-Muñoz, Beatriz, García-Samaniego, Javier, Forns, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Association for the Study of the Liver. Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357504/ https://www.ncbi.nlm.nih.gov/pubmed/32673740 http://dx.doi.org/10.1016/j.jhep.2020.07.007 |
Ejemplares similares
-
Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review
por: Picchio, Camila A., et al.
Publicado: (2021) -
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates
por: Lens, Sabela, et al.
Publicado: (2022) -
Let’s leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world
por: Crespo, Javier, et al.
Publicado: (2021) -
Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
por: Egmond, Elfi, et al.
Publicado: (2019) -
Early changes in brain structure, functional connectivity and neuropsychiatric symptoms after HCV infection cure with direct-acting antivirals
por: Cavero, M., et al.
Publicado: (2021)